Company Research Report: IXICO plc

Company Overview

• Name: IXICO plc

• Mission: IXICO is advancing therapies for neurological diseases by transforming data into clinically meaningful insights.

• Founded: No information is available.

• Founders: No information is available.

• Key People:

• CEO: Bram Goorden (appointed from 19 August 2024)

• Chief Scientific Officer: Robin Wolz

• Headquarters: 4th Floor, Griffin Court, 15 Long Lane, London, EC1A 9PN, England, UK.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: IXICO is known for its contribution to neuroscience, providing precision analytics that deliver intelligent insights in support of CNS clinical trials.

Products

IXICO offers a range of products primarily supporting CNS clinical trials:

1. Imaging Biomarkers:

• Description: Innovative neuroimaging methods and image analysis techniques.

• Key Features: Accurate and rich structural and functional information supporting CNS trials.

2. Analytics & AI:

• Description: AI technology that supports the entire spectrum of CNS clinical research.

• Key Features: Sophisticated analytics interpreting complex patient data for valuable insights.

3. Data Platforms:

• Description: Comprehensive image and digital data management platforms.

• Key Features: Secure, regulatory-compliant online digital platforms for managing complex data workflows in CNS clinical trials.

Recent Developments

• New Products Launched: No information is available.

• New Features Added:

• Development of an automatic deep learning method for the detection and quantification of white matter lesions for Multiple Sclerosis.

• New Partnerships:

• Global Alzheimer's Platform Foundation: Supporting the Bio-Hermes 2 trial with a contract valued over £1 million.

• Life Molecular Imaging Collaboration: Supplying Neuraceq® Amyloid PET tracer for clinical trials.

• Imeka Collaboration Agreement: Providing access to services for white matter imaging in Alzheimer's Disease and Multiple Sclerosis clinical trials.

Additional Insights

• IXICO has collaborated with numerous international organizations to advance neurological disease treatment. These include partnerships with Global Alzheimer's Platform Foundation, Huntington’s Disease Regulatory Science Consortium (HD-RSC), and European Prevention of Alzheimer’s Disease (EPAD) among others.

• IXICO's AI and innovative trial recruitment strategies are pioneering approaches in CNS clinical trials, driving advancements in therapy development efficiency and patient care improvement.

• The company’s platforms such as TrialTracker and Assessa are critical tools used to manage imaging workflows and support patient selection and post-marketing surveillance.

This report captures the essence of IXICO's business offerings, strategic developments, and collaborations, highlighting its pivotal role in advancing neurological research and clinical practices.